EdiShorts
UPSC Mains 2024GS Paper 4 (Ethics)Q19 · 20 marksCase StudyModel answer

Case study: Dr. Srinivasan is a senior scientist working for a reputed biotechnology company known for its cutting-edge research in pharmaceuticals.

DirectiveCase study
Marks20
Word limit250
PaperGS Paper 4 (Ethics)
What the examiner wants

Identify the stakeholders and the ethical issues, weigh the realistic options, and defend one course with concrete steps; each printed sub-part (a), (b), (c) must be answered on its own.

Common trap: Weak answers only say no to the shortcuts. A top answer treats each shortcut (data, consent, patents) on its own, offers a lawful way to speed up, and grounds part (c) in the Nuremberg Code, Helsinki and India's 2019 trial rules.

SyllabusCase Studies on above issues. (Public/Civil service values and Ethics in Public administration: ethical concerns and dilemmas in government and private institutions; laws, rules, regulations and conscience as sources of ethical guidance; accountability and ethical governance; corporate governance.)

The case

Dr. Srinivasan is a senior scientist working for a reputed biotechnology company known for its cutting-edge research in pharmaceuticals. Dr. Srinivasan is heading a research team working on a new drug aimed at treating a rapidly spreading variant of a new viral infectious disease. The disease has been rapidly spreading across the world and the cases reported in the country are increasing. There is huge pressure on Dr. Srinivasan’s team to expedite the trials for the drug as there is significant market for it, and the company wants to get the first-mover advantage in the market. During a team meeting, some senior team members suggest some shortcut for expediting the clinical trials for the drug and for getting the requisite approvals. These include manipulating data to exclude some negative outcomes and selectively reporting positive results, foregoing the process of informed consent and using compounds already patented by a rival company, rather than developing one’s own component. Dr. Srinivasan is not comfortable taking such shortcuts, at the same time he realises meeting the targets is impossible without using these means. (a) What would you do in such a situation? (b) Examine your options and consequences in the light of the ethical questions involved. (c) How can data ethics and drug ethics save humanity at large in such a scenario?

Model answer

20 marks · 250-word limit

A drug trial rests on two promises: the data are true and the participants consented. The proposed shortcuts break both, and using a rival's patented compounds adds infringement. In a fast-spreading outbreak the pressure is real, but a drug approved on manipulated data can harm the very patients it is meant to save.

Proposed shortcuts
  • Exclude negative outcomes
  • Report only positive results
  • Skip informed consent
  • Use rival's patented compounds
vs
Ethical fast-track
  • Complete, honest trial data
  • Valid informed consent
  • Own compound or a licence
  • More resources and early regulator engagement
Shortcut route versus ethical fast-track for the new drug

(a) What I would do

  • Refuse every shortcut: Reject data manipulation, selective reporting, bypassing consent and use of the rival's patented compounds, and have my objection recorded in the minutes.
  • Escalate with a plan: Brief top management and the ethics committee on legal, safety and reputational risks, and present a realistic revised timeline.
  • Accelerate lawfully: Seek more sites, staff and parallel work streams, and engage the regulator early on any expedited route available for serious unmet needs.
  • License, don't copy: If the rival's compound is essential, negotiate a licence or collaboration.
  • Last resort: If the company insists, decline to lead the work and use lawful whistle-blowing channels.

(b) Options and consequences in light of the ethical questions

OptionConsequences
Adopt the shortcutsTarget met, but unsafe drug, harm to patients, rejection of approvals, legal liability and lasting loss of trust
Stay silent and let others decideComplicity; moral responsibility remains
Resign quietlyPersonal integrity kept, but risk to patients continues
Refuse, escalate and accelerate ethicallySome delay and pressure, but credible data, valid approval and a durable product
  • Truthfulness: Hiding adverse outcomes is deception of regulators, doctors and patients.
  • Autonomy and dignity: Enrolling people without informed consent treats them merely as means, which Kant's humanity formula forbids.
  • Consequences: A fast but unsafe drug can do more harm than the delay it avoids; first-mover profit cannot outweigh lives.

(c) How data ethics and drug ethics protect humanity

  • Reliable evidence: Doctors and regulators worldwide act on published trial data; suppressed negative results mislead every future prescription.
  • Consent as foundation: The Nuremberg Code (1947) and the Declaration of Helsinki (1964) made voluntary informed consent the basis of research on humans.
  • Indian safeguards: The New Drugs and Clinical Trials Rules, 2019 and ICMR's National Ethical Guidelines (2017) require ethics committee approval and informed consent.
  • Trust during outbreaks: Honest science sustains public confidence in drugs and vaccines when cooperation matters most.
  • Fair innovation: Respecting patents rewards genuine research, while the Patents Act, 1970 itself provides compulsory licensing for public health needs.

In a spreading epidemic, a drug no one can trust saves no one. Dr. Srinivasan should refuse the shortcuts and lead an honest acceleration: truthful data, genuine consent and lawful use of others' inventions are not obstacles to beating the disease but the only way a cure truly helps humanity.

Answer length. This model answer runs to about 413 words so that every relevant angle is covered. In the exam, write to the 250-word limit: keep the opening, the strongest one or two points under each heading, the diagram and the conclusion.

Read more — sources

  • OfficialNew Drugs and Clinical Trials Rules, 2019 (Central Drugs Standard Control Organisation)
  • OfficialICMR — National Ethical Guidelines for Biomedical and Health Research Involving Human Participants (2017)
  • OfficialWorld Medical Association — Declaration of Helsinki (1964, as amended)
  • OfficialThe Patents Act, 1970

Related questions from earlier years

2015 · GS Paper 4 (Ethics) · QQ11 (Case Study)·20 marks·250 words·Case Study
One of the scientists working in the R & D laboratory of a major pharmaceutical company discovers that one of the company’s best selling veterinary drugs, B has the potential to cure a currently incurable liver disease that is prevalent in tribal areas.…
The dilemma is between shareholder value and the moral pull of a cure for poor tribal patients. Milton Friedman argued in 1970 that business's social responsibility is…
Read the case-study answer →
2016 · GS Paper 4 (Ethics) · QQ9 (Case Study)·20 marks·250 words·Case Study
A fresh engineering graduate gets a job in a prestigious chemical industry. She likes the work. The salary is also good. However, after a few months she accidentally discovers that a highly toxic waste is being secretly discharged into a river nearby. This…
Discharging toxic effluent into a river is an offence under Section 24 of the Water (Prevention and Control of Pollution) Act, 1974, and it violates the villagers'…
Read the case-study answer →
2026 · GS Paper 4 (Ethics) · Q2(a)·10 marks·150 words·Ethics
An endangered tribe has developed a severe skeletal deformity. A university research has identified a mineral supplement as a possible remedy, though clinical trials are yet to be conducted. Should the District Magistrate (DM) use this research on the tribe?…
No — not as proposed. Administering an untested supplement to an endangered, poorly informed population is precisely what research ethics exists to prevent.
Read the model answer →

More from GS Paper 4 (Ethics) 2024

Q1·10 marks·150 words·Ethics
Q1(a) The application of Artificial Intelligence as a dependable source of input for administrative rational decision-making is a debatable issue. Critically examine the statement from the ethical point of view.
Herbert Simon showed that administrators work under bounded rationality, with limited information, time and attention. AI promises to widen those limits, but raises an…
Read the model answer →
Q2·10 marks·150 words·Ethics
Q1(b) “Ethics encompasses several key dimensions that are crucial in guiding individuals and organizations towards morally responsible behaviour.” Explain the key dimensions of ethics that influence human actions. Discuss how these dimensions shape ethical…
Ethics is the study of right conduct and good character. It is not a single rule but a set of dimensions, from the intention behind an act and its consequences to the…
Read the model answer →
Q3·10 marks·150 words·Ethics
Q2(a) “It is not enough to talk about peace, one must believe in it; and it is not enough to believe in it, one must act upon it.” In the present context, the major weapon industries of the developed nations are adversely influencing continuation of number…
The line, usually attributed to Eleanor Roosevelt, says peace needs talk, belief and action together. Today the states that speak most of peace also sell most weapons.…
Read the model answer →
Q4·10 marks·150 words·Ethics
Q2(b) Global warming and climate change are the outcomes of human greed in the name of development, indicating the direction in which extinction of organisms including human beings is heading towards loss of life on Earth. How do you put an end to this to…
The IPCC's Sixth Assessment (2023) found that human activity has already warmed the planet by about 1.1°C over pre-industrial levels, and the IPBES (2019) warned that…
Read the model answer →
Q5·10 marks·150 words·Ethics
Q3(a) Given below are three quotations of great thinkers. What do each of these quotations convey to you in the present context? “Learn everything that is good from others, but bring it in, and in your own way absorb it, do not become others.” — Swami…
Swami Vivekananda, who carried Vedanta to the West at the Chicago Parliament of Religions in 1893, was an advocate of openness without imitation. The quotation asks us…
Read the model answer →

Model answer by the EdiShorts editorial team. It is one well-argued treatment of the question, written to the official word limit — not an official UPSC answer key.